NVG, LLC for ALEXION PHARMACEUTICALS
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 22, 2018 | $50,000 | Replaced |
| 4th Quarter - Amendment (this page) | Oct 10, 2018 | $60,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FDA - rare and orphan disease issues; Prescription drug coverage and payment policies; Medical innovation issues; H.R. 1231/S. 456 - Research to Accelerate Cures and Equity for Children Act; Orphan Drug tax provisions in H.R. 1.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA GERMAN FOSTER | — |
| PATRICIA GRIFFIN | — |
| ANDREA LARUE | — |
Copyright/Patent/Trademark CPT
Intellectual property and potential changes to the patent system, generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA LARUE | — |
Medicare/Medicaid MMM
Orphan drug payments under Medicare Part A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA GERMAN FOSTER | — |
| ANDREA LARUE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.